|
Name |
2-Oxo-4-methoxy-2H-pyran 6-propionic acid
|
| Molecular Formula | C9H10O5 | |
| IUPAC Name* |
3-(4-methoxy-6-oxopyran-2-yl)propanoic acid
|
|
| SMILES |
COC1=CC(=O)OC(=C1)CCC(=O)O
|
|
| InChI |
InChI=1S/C9H10O5/c1-13-7-4-6(2-3-8(10)11)14-9(12)5-7/h4-5H,2-3H2,1H3,(H,10,11)
|
|
| InChIKey |
ANMIXQYGZDPTLJ-UHFFFAOYSA-N
|
|
| Synonyms |
CHEMBL2331727; ACon1_001779; BDBM50428357; NCGC00180151-01; 2-Oxo-4-methoxy-2H-pyran 6-propionic acid; 3-(4-methoxy-2-oxo-2H-pyran-6-yl)-propanoic acid; BRD-K96439574-001-01-4
|
|
| CAS | NA | |
| PubChem CID | 24123426 | |
| ChEMBL ID | CHEMBL2331727 |
Chemical Classification: |
|
|
|---|
| Molecular Weight: | 198.17 | ALogp: | 0.2 |
| HBD: | 1 | HBA: | 5 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 72.8 | Aromatic Rings: | 1 |
| Heavy Atoms: | 14 | QED Weighted: | 0.782 |
| Caco-2 Permeability: | -4.746 | MDCK Permeability: | 0.00030779 |
| Pgp-inhibitor: | 0 | Pgp-substrate: | 0.493 |
| Human Intestinal Absorption (HIA): | 0.033 | 20% Bioavailability (F20%): | 0.199 |
| 30% Bioavailability (F30%): | 0.997 |
| Blood-Brain-Barrier Penetration (BBB): | 0.208 | Plasma Protein Binding (PPB): | 71.55% |
| Volume Distribution (VD): | 0.25 | Fu: | 27.44% |
| CYP1A2-inhibitor: | 0.041 | CYP1A2-substrate: | 0.769 |
| CYP2C19-inhibitor: | 0.031 | CYP2C19-substrate: | 0.057 |
| CYP2C9-inhibitor: | 0.012 | CYP2C9-substrate: | 0.94 |
| CYP2D6-inhibitor: | 0.036 | CYP2D6-substrate: | 0.593 |
| CYP3A4-inhibitor: | 0.01 | CYP3A4-substrate: | 0.063 |
| Clearance (CL): | 8.532 | Half-life (T1/2): | 0.821 |
| hERG Blockers: | 0.014 | Human Hepatotoxicity (H-HT): | 0.335 |
| Drug-inuced Liver Injury (DILI): | 0.537 | AMES Toxicity: | 0.018 |
| Rat Oral Acute Toxicity: | 0.042 | Maximum Recommended Daily Dose: | 0.347 |
| Skin Sensitization: | 0.169 | Carcinogencity: | 0.151 |
| Eye Corrosion: | 0.76 | Eye Irritation: | 0.862 |
| Respiratory Toxicity: | 0.031 |